Biotechnology Company Intensity Therapeutics Secures $10M in Series A Financing

Intensity-logoIntensity Therapeutics, Inc., a Westport, CT-based biotechnology company developing proprietary cancer immunotherapy products, secured $10m in Series A financing.

Backers included Batterson Venture Capital, VCapital, FastForward Innovations, SalvaRx Group PLC, Declan Doogan M.D. and Jim Mellon as well as several other accredited investors and family offices.

The company intends to use the capital to fund operations, manufacture the clinical supplies, permit the needed regulatory filings and conduct a series of clinical trial cohorts in cancer patients with various tumor types.

Led by President and CEO Lewis H. Bender, Intensity uses proprietary platform technology to create new products capable of attenuating (killing) a tumor in a manner that allows for the adaptive immune system to recognize the cancer and attack tumors.
Its INT230-6 is a novel, anti-cancer drug product able to disperse through tumors and diffuse into cancer cells.

FinSMEs

28/06/2016

Join the discussion